Limits...
Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.

Koon CM, Ko CH, Sun XX, Hoi SW, Tam JC, Cheung DW, Cheng KF, Pang SY, Lo WM, Chook P, Lau CB, Chan WY, Leung PC, Kwok TC, Fung KP - Evid Based Complement Alternat Med (2013)

Bottom Line: For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group.No significant biological process and cellular components were identified in the placebo-treated group.This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

View Article: PubMed Central - PubMed

Affiliation: Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong ; State Key Laboratory of Phytochemistry & Plant Resources in West China, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

ABSTRACT
The Danshen-Gegen formula (DG) is a traditional Chinese herbal formula which has long been used to treat cardiovascular disease. DG was found to be a cardiovascular tonic in our recent research. However, a comprehensive investigation of the molecular mechanism of DG in cardiovascular disease has not been performed. The aim of this study was to clarify the transcriptional profiling of genes modulated by DG on postmenopausal women by using DNAmicroarray technology. We obtained 29 whole blood samples both from DG-treated and placebo-treated subjects. Blood lipid profile and intima-media thickness (IMT) were measured. Affymetrix GeneChip was used to identify differentially expressed genes (DEGs), followed by validation by the real-time PCR method. The results showed that DG-treated group has a significant improvement in IMT and lipid profile as compared to placebo-treated group. For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group. Two important biological processes of "regulation of systemic arterial blood pressure by hormone" and "regulation of smooth muscle proliferation" have been identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

No MeSH data available.


Related in: MedlinePlus

Cluster analyses of Pre and Post samples in three individual subjects of the DG-treated group and the placebo-treated group. The overlapped area of the clusters (red and blue) indicates the greater similarity of the gene expression profile.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3794622&req=5

fig5: Cluster analyses of Pre and Post samples in three individual subjects of the DG-treated group and the placebo-treated group. The overlapped area of the clusters (red and blue) indicates the greater similarity of the gene expression profile.

Mentions: To evaluate intraexperimental technical variation, the gene expression profile of three repeated hybridizations of each sample was performed by using principal component analysis (PCA). The PCA results revealed that there was no overlapping in the clusters of three repeated hybridizations (red balls) of the Pre and Post samples of the DG-treated group and the placebo-treated group (Figure 4). The cluster analyses of Pre and Post whole blood samples of the DG-treated group and the placebo-treated group (n = 3) are shown in Figure 5. The gene expression profile (as shown in cluster) of the Pre samples was well separated from that of the Post samples in the DG-treated group, whereas the cluster of the Pre sample was overlapped with that of the Post samples in the placebo-treated group (Figure 5).


Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.

Koon CM, Ko CH, Sun XX, Hoi SW, Tam JC, Cheung DW, Cheng KF, Pang SY, Lo WM, Chook P, Lau CB, Chan WY, Leung PC, Kwok TC, Fung KP - Evid Based Complement Alternat Med (2013)

Cluster analyses of Pre and Post samples in three individual subjects of the DG-treated group and the placebo-treated group. The overlapped area of the clusters (red and blue) indicates the greater similarity of the gene expression profile.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3794622&req=5

fig5: Cluster analyses of Pre and Post samples in three individual subjects of the DG-treated group and the placebo-treated group. The overlapped area of the clusters (red and blue) indicates the greater similarity of the gene expression profile.
Mentions: To evaluate intraexperimental technical variation, the gene expression profile of three repeated hybridizations of each sample was performed by using principal component analysis (PCA). The PCA results revealed that there was no overlapping in the clusters of three repeated hybridizations (red balls) of the Pre and Post samples of the DG-treated group and the placebo-treated group (Figure 4). The cluster analyses of Pre and Post whole blood samples of the DG-treated group and the placebo-treated group (n = 3) are shown in Figure 5. The gene expression profile (as shown in cluster) of the Pre samples was well separated from that of the Post samples in the DG-treated group, whereas the cluster of the Pre sample was overlapped with that of the Post samples in the placebo-treated group (Figure 5).

Bottom Line: For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group.No significant biological process and cellular components were identified in the placebo-treated group.This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

View Article: PubMed Central - PubMed

Affiliation: Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong ; State Key Laboratory of Phytochemistry & Plant Resources in West China, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

ABSTRACT
The Danshen-Gegen formula (DG) is a traditional Chinese herbal formula which has long been used to treat cardiovascular disease. DG was found to be a cardiovascular tonic in our recent research. However, a comprehensive investigation of the molecular mechanism of DG in cardiovascular disease has not been performed. The aim of this study was to clarify the transcriptional profiling of genes modulated by DG on postmenopausal women by using DNAmicroarray technology. We obtained 29 whole blood samples both from DG-treated and placebo-treated subjects. Blood lipid profile and intima-media thickness (IMT) were measured. Affymetrix GeneChip was used to identify differentially expressed genes (DEGs), followed by validation by the real-time PCR method. The results showed that DG-treated group has a significant improvement in IMT and lipid profile as compared to placebo-treated group. For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group. Two important biological processes of "regulation of systemic arterial blood pressure by hormone" and "regulation of smooth muscle proliferation" have been identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

No MeSH data available.


Related in: MedlinePlus